Stoke Therapeutics (Nasdaq: STOK) has completed enrollment of 162 patients into the Phase 3 EMPEROR study evaluating zorevunersen, an investigational ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE